13 Amendments of Konrad SZYMAŃSKI related to 2011/0402(CNS)
Amendment 231 #
Proposal for a decision
Article 5 – paragraph 3 a (new)
Article 5 – paragraph 3 a (new)
3a. The examination procedure referred to in Article 9(2) shall apply for the approval of the funding of actions involving the use of human embryos or the use of human embryonic stem cells.
Amendment 516 #
Proposal for a decision
Annex 1 – section 2 – point 1 – point 1.4 – point 1.4.3 – paragraph 1
Annex 1 – section 2 – point 1 – point 1.4 – point 1.4.3 – paragraph 1
The objective is to develop platform technologies (e.g. genomics, meta- genomics, proteomics, molecular tools) triggering leadership and competitive advantage on a wide number of economic sectors. It includes aspects, such as underpinning the development of bio- resources with optimised properties and applications beyond conventional alternatives; enabling exploration, understanding and exploitation in a sustainable manner of terrestrial and marine biodiversity for novel applications; Priority support will be given to new diagnostic methods where a prevention or diagnosis for the patient in question either already exists or is likely to be developed.
Amendment 608 #
Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.2 – paragraph 1
Annex 1 – section 3 – point 1 – point 1.2 – paragraph 1
The development of screening programmes depends on the identification of early biomarkers of risk and of disease onset, and their deployment depends on the testing and validation of screening methods and programmes. Identifying individuals and populations at high-risk of disease will allow personalised, stratified and collective strategies for efficacious and cost effective disease prevention to be developed. In this connection, priority will be given to screening programmes where prevention or therapy for the patient concerned are available or are likely to be developed.
Amendment 619 #
Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.6 – paragraph 1
Annex 1 – section 3 – point 1 – point 1.6 – paragraph 1
An improved understanding of health, disease and disease processes at all ages is needed to develop new and more effective diagnostics. Innovative and existing technologies will be developed with the goal of significantly improving disease outcomes through earlier, more accurate diagnosis and by allowing for more patient-adapted treatment. In this connection, priority will be given to diagnostic methods where prevention or therapeutic measures for the patients concerned are available or are likely to be available in the near future.
Amendment 627 #
Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.8 – paragraph 1
Annex 1 – section 3 – point 1 – point 1.8 – paragraph 1
There is a need to support the improvement of cross-cutting support technologies for drugs, vaccines and other therapeutic approaches, including transplantation, gene and cell therapy, particularly adult stem cell therapy, umbilical cord blood cell and iPS cell therapies; to increase success in the drug and vaccine development process (including alternative methods to replace classical safety and effectiveness testing e.g. the development of new methods); to develop regenerative medicine approaches, including approaches based on stem cells; to develop improved medical and assistive devices and systems; to maintain and enhance our ability to combat communicable, rare, major and chronic diseases and undertake medical interventions that depend on the availability of effective antimicrobial drugs; and to develop comprehensive approaches to treat co-morbidities at all ages and avoid poly-pharmacy. These improvements will facilitate the development of new, more efficient, effective and sustainable treatments for disease and for the management of disability. There is a need to develop ideas in the field of regenerative medicine, particularly based on adult stem cells, umbilical cord blood cells and iPS cells.
Amendment 639 #
Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.9 – paragraph 1
Annex 1 – section 3 – point 1 – point 1.9 – paragraph 1
Clinical trials are the means to transfer biomedical knowledge to application in patients and support for these will be provided, as well as for the improvement of their practice. Examples include the development of better methodologies to allow trials to focus on relevant population groups, including those suffering from other concomitant diseases and/or already undergoing treatment, the determination of comparative effectiveness of interventions and solutions, as well as enhancing the use of databases and electronic health records as data sources for trials and knowledge transfer. Similarly, support for the transfer of other types of interventions such as those related to independent living into real world environments will be provided. Particular importance will be given to clinical tests in the field of rare diseases and child illnesses including those associated with premature birth.
Amendment 653 #
Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.15 a (new)
Annex 1 – section 3 – point 1 – point 1.15 a (new)
Amendment 778 #
Proposal for a decision
Annex 1 – section 3 – point 3 – point 3.2 – point 3.2.3 – introductory part
Annex 1 – section 3 – point 3 – point 3.2 – point 3.2.3 – introductory part
3.2.3. Develop competitive and environmentally safe technologies for CO2 capture, utilisation, transport and storage
Amendment 779 #
Proposal for a decision
Annex 1 – section 3 – point 3 – point 3.2 – point 3.2.3 – paragraph 1
Annex 1 – section 3 – point 3 – point 3.2 – point 3.2.3 – paragraph 1
Carbon capture and storage (CCS) is aand capture and usage (CCU) are key options that hasve to be widely deployed on a commercial scale at global level to meet the challenge of a decarbonised power generation and low carbon industry by 2050. The objective is to minimise the extra-cost of CCS in the power sector for coal-fired and gas-fired power plants compared to equivalent plants without CCS and energy intensive industrial installations.
Amendment 782 #
Proposal for a decision
Annex 1 – section 3 – point 3 – point 3.2 – point 3.2.3 – paragraph 1 a (new)
Annex 1 – section 3 – point 3 – point 3.2 – point 3.2.3 – paragraph 1 a (new)
Carbon capture and utilisation (CCU) offers potential for value-added applications of CO2 captured from power plants and industrial installations and could make a contribution to the decarbonisation of the economy. CCU systems and technologies to convert CO2 into products such as chemicals, fertilizer, fuels and bio-oils should be explored.
Amendment 783 #
Proposal for a decision
Annex 1 – section 3 – point 3 – point 3.2 – point 3.2.3 – paragraph 1 b (new)
Annex 1 – section 3 – point 3 – point 3.2 – point 3.2.3 – paragraph 1 b (new)
Carbon capture can go along synergetically with carbon storage in chemical products (carbon to chemicals). Moreover, there is the option for syngas- based production of fuels for storage, which can be used to equalise fluctuating power production by incorporating renewable hydrogen. The fuel produced can be used for peak electricity generation. The development of low-cost and fuel-tolerant gasification technologies are essential for these systems.
Amendment 784 #
Proposal for a decision
Annex 1 – section 3 – point 3 – point 3.2 – point 3.2.3 – paragraph 1 c (new)
Annex 1 – section 3 – point 3 – point 3.2 – point 3.2.3 – paragraph 1 c (new)
In addition, a reliable CO2-infrastructure needs to be developed timely as most fossil fuel power plants and other CO2-sources will not be close to storage areas, which in many cases are below the seabed, whereas power plants are usually located where electricity demand is higher.
Amendment 873 #
Proposal for a decision
Annex 1 – section 3 – point 5 – point 5.3 – point 5.3.3 – paragraph 1 a (new)
Annex 1 – section 3 – point 5 – point 5.3 – point 5.3.3 – paragraph 1 a (new)
In this regard, the increasing dependence of the European chemical industry on external sources of oil and natural gas as chemical raw materials should be taken into account. The European chemical industry has become more and more interested in recent years in the use of indigenous coal as an alternative chemical feedstock. The non-energetic use of indigenous coal can offer long- term development prospects to many European chemical sites, given the depletion of global oil reserves and political instabilities in the producing countries. In the future, process technologies and plants should be developed which make alternative hydrocarbon sources such as indigenous coal resources useful to the European chemical industry.